The impact of vitamin D supplementation on mortality rate and clinical outcomes of COVID-19 patients: A systematic review and meta-analysis

Leila Nikniaz¹, Mohammad Amin Akbarzadeh²,³,⁴, Hossein Hosseinifard⁵, Mohammad-Salar Hosseini²,³,⁴ *

¹ Tabriz Health Services Management Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
² Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
³ Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
⁴ Iranian Evidence-Based Medicine (EBM) Centre, Joanna Briggs Institute Affiliated Group, Tabriz, Iran
⁵ Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Corresponding Author: Mohammad-Salar Hosseini, Student Research Committee, Tabriz University of Medical Sciences, Golgasht Street, Postal code 5166/15731, Tabriz, EA, Iran. Telephone Number: +984133366581, Fax Number: +984133341994. Email: hosseini.msalar@gmail.com

Running title: Impact of vitamin D on COVID-19 mortality and hospitalization

Keywords: COVID-19, dietary supplements, SARS-CoV-2, treatment outcome, vitamin D
Abstract

**Background:** Several studies have suggested the positive impact of vitamin D on patients infected with SARS-CoV-2. This systematic review aims to evaluate the effects of vitamin D supplementation on clinical outcomes and mortality rate of COVID-19 patients.

**Methods:** A comprehensive search was conducted through the databases of PubMed, Scopus, Web of Knowledge, Embase, Ovid, and The Cochrane Library without time and language limitation, until December 16, 2020. The results were screened, and the outcomes of interest were extracted. Using the Joanna Briggs Institute (JBI) Critical Appraisal Tools, the remaining results were appraised critically. Statistical analysis was performed using the Comprehensive Meta-Analysis (CMA) software version 2.0.

**Results:** Of the 2311 results, four studies and 259 patients were enrolled, including 139 patients in vitamin D intervention groups. The pooled analysis of three studies, reporting the patients’ survival and mortality rate, showed a significantly lower mortality rate among the intervention groups compared with the control groups (OR=0.264, 95% CI=0.099–0.708, p-value=0.008). Two of the studies reported the clinical outcomes based on the World Health Organization’s Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19, where both of them showed a significant decrease in OSCI score in the vitamin D intervention groups. One study reported a lower rate of intensive care unit (ICU) admission, and one study reported a significant decrease in serum levels of Fibrinogen.

**Conclusion:** Prescribing vitamin D supplementation to patients with COVID-19 infection seems to decrease the mortality rate, the severity of the disease, and serum levels of the inflammatory markers. Further studies are needed to determine the ideal type, dosage, and duration of supplementation.

**Keywords:** COVID-19, dietary supplements, SARS-CoV-2, treatment outcome, vitamin d
Introduction
With the global widespread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the progressive rise in infection and mortality toll, efficient and effective management of the current medical emergency has become an absolute priority. Great efforts have been taken in most of the involved countries to develop a comprehensive therapeutic approach to prevent and cure the disease. Considering the absence of definite treatment, the high number of the infected people, limited capacity of the healthcare centers, and extensive costs of providing treatments, the researchers and the clinicians are struggling to present appropriate clinical approaches with favorable cost-benefit outcomes, which can help in both preventing the disease and treat the patients, along with lowering the burden of disease on the community. Since no safe medication has been developed yet, the search for the beneficial use of currently-available drugs has been prioritized. Therefore, different ways of improving the immune system's function have turned to a primary research goal.

One of the potential candidates is vitamin D; a fat-soluble micronutrient that could possibly facilitate the function of the immune system. Although the emerging evidence is growing, a potential association between vitamin D deficiency and severe outcomes in patients with COVID-19 have been reported thus far. The immunomodulatory impact of vitamin D has been investigated in treatment of upper respiratory infections, even before the current pandemic. Vitamin D and related metabolites have a regulatory role in the immune system, thanks to the common receptors found in various innate immune system cells. Furthermore, it can suppress the adaptive immune response in the affected areas (e.g., lung epithelial cells) and, consequently, avoid the pro-inflammatory agents' harm to prevent further damage. Also, vitamin D plays a protective role against the direct damage of the inflammatory factors – which are secreted during the viral diseases – by lowering the expression rate of inflammatory factors, stimulating the expression of anti-inflammatory factors, and more importantly, stimulating the proliferation of the immune cells and their products.

Since vitamin D has both stimulating and regulating effects on the immune system, it is reasonable to direct more attention to evaluating this supplement's in-hospital and home prescription. If the positive impact of vitamin D on COVID-19 patients gets confirmed, it can be used as a cheap and widely available therapeutic aid. Considering the probability of adding this supplement to treatment guidelines, it may be beneficial to evaluate the possible effects of vitamin D therapy on infected patients.
According to the considerable evidence available regarding the issue and the lack of a systematic review in this field, this systematic review was conducted to assess the impact of prescribing vitamin D supplementation on mortality and clinical outcomes of COVID-19 patients.

**Methods**

The current systematic review was conducted according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).\textsuperscript{14} The research question of the study was based on PICO and is available in Table 1. Figure 1 presents the PRISMA Flow Diagram of the study. The Ethics Committee of Tabriz University of Medical Sciences (Tabriz, Iran) approved the study. The systematic review protocol is registered in the International Prospective Register of Systematic Reviews (PROSPERO), by the registration code CRD42021228077.

**Search Strategy**

The current systematic review was designed and conducted in December 2020. A comprehensive search was conducted among the databases of PubMed, Scopus, Web of Knowledge, Embase, Ovid, and The Cochrane Library, using a combination of the following free keywords and related MeSH (Medical Subject Headings) Terms: vitamin D, vitamin D3, vit d, cholecalciferol, ergocalciferol, 25-hydroxyvitamin, dihydrotachysterol, calcidiol, 25-hydroxycholecalciferol, covid, covid-19, sars-cov-2, 2019-ncov, coronavirus. The search was conducted on December 16\textsuperscript{th}, 2020, without limitation in time and language. Also, in order to increase the accuracy of identifying the related articles, the reference lists of the results were searched, and the experts in the field were contacted, and the related articles were included. The PubMed search strategy is provided as follows: ("Vitamin D"[Mesh] OR Vitamin D OR vitamin D3 OR Vit D OR Cholecalciferol OR Ergocalciferol OR 25-Hydroxyvitamin OR Dihydrotachysterol OR calcidiol OR 25-hydroxycholecalciferol) AND (("COVID-19" [Supplementary Concept]) OR "severe acute respiratory syndrome coronavirus 2" [Supplementary Concept] OR covid OR covid-19 OR sars-cov-2 OR 2019-ncov OR coronavirus). The search strategy of other databases is available in Additional file 1.

**Inclusion and exclusion criteria**

All clinical trials, quasi-experimental, and pilot studies were included, if there was an administration of any type of vitamin D supplementation to at least one group of confirmed COVID-19-positive patients was present in the study, regardless of the number of patients, age groups, and language. Studies without vitamin D intervention and studies other than clinical trials, quasi-experimental, and pilot studies (e.g., case-control studies, cohort studies,
observational studies, case reports, reviews, letter to editors, etc.), animal studies, and laboratory studies were excluded.

**Study selection and data extraction**
In order to identify the studies relevant to the subject of the review, two researchers independently screened the results by title and abstract, according to their accordance with the study subject and the inclusion/exclusion criteria. Afterwards, the full-texts of the remaining records were obtained and assessed for relevancy, and the remaining records were finally included in the study.

Two independent researchers extracted the following data from the included studies: Author(s), year of publication, country of the study, mean ages, characteristics of the populations, type of intervention, and different outcomes.

**Quality assessment**
Two independent researchers critically appraised all included studies, using the Joanna Briggs Institute (JBI) Critical Appraisal Tools for Randomized Controlled Trials (RCTs) and Quasi-Experimental Studies.

**Statistical analyses**
Statistical analysis was performed on the effect of vitamin D supplementation on the mortality rate, data of which was available in three of the studies, using the Comprehensive Meta-Analysis (CMA) software version 2.0. The odds ratio (OR) was calculated for each of the studies by events and total numbers of patients in two groups. The degree of heterogeneity was defined as significant with a p-value less than 0.05 or I² over 50%. The pooled OR and the 95% confidence interval (95% CI) were calculated, and a p-value less than 0.05 was considered as statistically significant for outcomes. The results were presented as a forest plot.

**Results**

**Study selection**
Of the 2311 results, 1305 were removed due to the duplicity among the various databases. After screening the titles and abstracts, 925 more studies were excluded as a result of incompatibility with the inclusion criteria. After screening the remaining records based on the full-texts of the articles, 77 more records were excluded due to incompatibility of the study design with the inclusion criteria, and finally, four studies were critically appraised for risk of bias and all four were included in the current study. Figure 1 presents the PRISMA Flow Diagram of the study.

**Study characteristics and quality assessment**
Two of the studies were appraised by the JBI Critical Appraisal Tools for Randomized Controlled Trials (RCTs) and two of them by the JBI Critical Appraisal Tools for Quasi-
Experimental Studies. All the appraised studies had more low-risk domains than the high-risk ones, and therefore, are reported as low-risk for bias. Table 2 and Table 3 present the quality assessment results. The results of the risk of bias assessment are present in Table 2 and Table 3.

A total of 259 individuals (140 females and 119 males) were present in the included studies, 139 of which were allocated to the intervention groups. Two of the studies were conducted in France,\textsuperscript{15, 16} one in India\textsuperscript{17} and one in Spain.\textsuperscript{18} From the four included studies, Three of the studies reported the mortality rate and survival, two of them reported the clinical outcomes based on the World Health Organization's Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19,\textsuperscript{19} one of them reported the rate of intensive care unit (ICU) admission, and one of the studies reported the changes of the inflammatory markers. Among the included studies, two studies were conducted among a population of aged patients (mean ages 87.7 and 88), and one study among vitamin D deficient patients ($25(OH)D < 20$ ng/mL). Bolus vitamin D3 was prescribed in three of the studies, two of them along with antibiotics, Hydroxychloroquine, and Corticosteroids (single-dose, oral route, 80,000 IU for one day), and one of them among the vitamin D deficient COVID-19 patients (oral route, 60,000 IU for seven days). In the study with vitamin D deficient patients, oral Cholecalciferol (60,000 IU) was prescribed for seven days. The supplementation was continued to 14 days for the patients who did not reach the treatment goal of $25(OH)D > 50$ ng/mL in the first seven days. From the baseline of $25(OH)D3 = 8.6 \, [7.1 – 13.1] \, (\text{ng/ml})$, the levels of $25(OH)D3$ were increased to over 50 in ten patients after seven days of supplementation, and over 50 in two more patients after an overall of 14 days of supplementation. Along with Hydroxychloroquine and Azithromycin, oral Calcifediol was prescribed in one study by the following protocol: 0.532 mg on the day of admission, 0.266 mg on third and seventh days, and then 0.266 mg once every week. The characteristics of the included studies are presented in Table 4.

**Mortality rate and survival**

Three of the included studies reported the mortality rate. In the study of C. Annweiler et al. the mortality rate was 55.56\% in the control group, which was significantly ($p = 0.023$) higher than the intervention group (17.75\%) during the follow-up time (36.6 ± 17 days).\textsuperscript{15} In the mentioned study, the Hazard ratio (HR) for mortality in elderly COVID-19 patients, following the use of bolus vitamin D3 supplements, was $HR = 0.11$ [95\% CI: 0.03-0.48], which indicated that vitamin D supplementation is strongly more effective against mortality, compared with other interventions of the same study, including the use of corticosteroids (HR = 6.64), use of Hydroxychloroquine (HR = 15.07), use of antibiotics (HR = 0.36), and hospitalization (HR =
0.38). In another study, the mortality rate was 7.69% in the control group, which was higher than the intervention group (0%), and the patients in the intervention group were all discharged without complications. In the study of G. Annweiler et al., the mortality rate was 31.25% in the control group, which was insignificantly (p = 0.28) higher than the intervention group (18.75%), showing a hazard ratio of 0.37 for 14-day mortality.

As presented in Figure 2, a meta-analysis was performed on the three studies reporting the mortality rate. The heterogeneity among the studies was not significant (Q = 1.514, df = 2, I² = 0.000, p-value = 0.469). The intervention group consisted of 123, and the control group consisted of 67 patients. Based on the results of the meta-analysis, vitamin D supplementation was associated with a significant reduction in the odds of mortality, compared with the control group (pooled OR =0.264, 95% CI = 0.099-0.708, p-value = 0.008).

Intensive Care Unit (ICU) admission

Only one study reported the Intensive Care Unit (ICU) admission. The Intensive Care Unit (ICU) admission rate was 50% in the control group, in contrast with 2% in the intervention group. In this study, after performing a multivariate logistic regression analysis and adjusting the possible confounding effects on the admission to the ICU, an odds ratio (OR) of 0.03 (95% CI: 0.003 - 0.25) was observed, in favor of no need for ICU admission.

Secondary outcomes and severity of the disease

The World Health Organization’s Ordinal Scale for Clinical Improvement (OSCI) score for COVID-19 was considered as a secondary outcome in two of the studies. The OSCI score was adjusted for participants’ characteristics, and a significant decrease in the score was observed associated with the bolus supplementation of vitamin D (p = 0.001). The severity of the disease was also assessed by the serum levels of inflammatory markers in one of the studies. Unlike C-reactive protein (CRP), Procalcitonin, and D-dimer, the level of Fibrinogen was significantly decreased among the intervention group after the study duration (p-value = 0.007).

Discussion

To the best of our knowledge, this is the first systematic review exploring the effect of vitamin D supplementation on the mortality rate and clinical outcomes of COVID-19 patients. This review was conducted in order to clarify the effect of vitamin D supplementation on the clinical outcomes of the patients with COVID-19 infection, including the mortality rate, the severity of the disease, and the need for intensive care. Four studies, including 259 patients with COVID-19 infection, were included and assessed. Our analysis indicated that vitamin D supplementation could positively affect the mortality rate of COVID-19 patients. Moreover,
vitamin D supplementation can significantly enhance the patients’ survival, reduce the clinical complications, decrease ICU admission rate, and lower the serum levels of the inflammatory markers.

Vitamin D is a micronutrient that has been investigated vastly due to its unique physiological impacts (i.e., regulating the endocrinological processes, the Renin-Angiotensin-Aldosterone-System (RAAS) pathway, etc.), and regulating the different pathways of the both innate and acquired immune system, which would eventually lead to anti-inflammatory, antioxidant, and antiviral characteristics. Considering the immunologic aspects of these characteristics, numerous studies have been conducted in order to investigate the effects of vitamin D on different bacterial and viral infections. Acute upper and lower respiratory infections caused by viral pathogens are among the most researched infections in this regard and the effects of vitamin D level on the viral diseases including influenza, respiratory syncytial virus, Dengue fever, Hepatitis C and HIV have been investigated in multiple studies for each of these pathogens. However, despite the general regulatory role of vitamin D, studies are reporting different results, leading to controversy about the clinical outcomes of vitamin D; for instance, in case of influenza, despite the studies that showed significant results in favor of vitamin D effectiveness in prevention and treatment of influenza, some studies showed no significant benefit in the prescription of vitamin D, like the study carried out in Vietnam, where 1641 children with influenza were randomized to vitamin D and placebo groups. Eventually, no decrease in influenza cases was observed among the group receiving vitamin D. Among the included studies of this review, three studies reported the mortality rate, all showing a decrease in the intervention groups’ mortality rate. Considering individually, the decrease in mortality rate was significant in only one of the studies. However, the pooled analysis indicated a solid and significant decrease in the mortality rate among patients with vitamin D supplementation. Although the results are completely in favor of vitamin D, decreasing the mortality rate, an ultimate conclusion cannot be drawn due to the lack of studies. Also, the heterogeneity could be affected by the low number of studies. Moreover, some factors in the included studies could affect the patients’ outcomes; two studies were conducted on the aged people, which might affect the mortality rate due to the presence of more comorbidities among the studied population. Similarly, one study was conducted on vitamin D-deficient patients, which may show higher effectiveness of the intervention, compared with an average population. Another factor that might affect the results is the difference in the dose of supplementation, which is inevitable due to the number of studies.
In contrast to the low number of clinical trials conducted about the efficacy of vitamin D prescription in COVID-19 patients, there is a significant number of observational studies available, which evaluate the relationship between vitamin D level and the patients’ outcomes, justify to clarify the research path for further evaluation by conducting randomized clinical trials. Most of these studies have indicated a significant association between vitamin D deficiency and severe clinical outcomes of COVID-19.\textsuperscript{32, 33} A recent meta-analysis on observational studies has reported a significant association between low serum levels of vitamin D and an increased risk of COVID-19 infection.\textsuperscript{34} With an OR of 1.43 for the risk of COVID-19 infection among the vitamin D deficient patients, Liu et al. suggest a daily vitamin D supplementation.\textsuperscript{34}

Age, sun exposure, and diet are the main risk factors for vitamin D deficiency and considering these factors, several studies have been conducted to evaluate the possible link between these factors and the clinical outcomes of COVID-19.\textsuperscript{35-37} Both young and aged people are prone to vitamin D deficiency, which indicates that regardless of the existence of comorbidities, correcting the deficiency could be vital for all patients’ health.\textsuperscript{38} However, the difference between these groups is in the etiology of the deficiency, which is due to lack of sun exposure and inadequate dietary intake among the young people, but rather physiologic among the aged people. Hence, both groups are disposed to the risk of severe outcomes of COVID-19. However, it may be challenging to establish the association, solely considering the vitamin D deficiency in the elderly group since a variety of confounding factors are present because of the comorbidities the elderly group may have. Basically, increased age is an independent risk factor for both the vitamin D deficiency and severe outcomes of COVID-19.\textsuperscript{39, 40} The study conducted by lips et al., where the mean levels of vitamin D were measured in the populations of 40 countries and care home residents, mostly consisted of the elderly, have shown a deficiency of over 50%.\textsuperscript{41} The sun exposure is another determinant of vitamin D storage, and with lack of exposure, the deficiency is likely expected. Multiple ecological studies have shown that countries with higher latitude and decreased vitamin D levels have an increased infection rate and poor outcomes.\textsuperscript{42} The study conducted by Rhodes et al. demonstrated that countries below 35 degrees north have a lower mortality rate, and the people above that degree may suffer excess mortality because of the insufficient sunlight to produce vitamin D during winter adequately. This might be indicative of a probable role of vitamin D deficiency in patients’ poor outcomes.\textsuperscript{43, 44}

Apart from the etiology, the deficiency has a great impact on the strength of the immune system and therefore, leads to poor outcomes of COVID-19.\textsuperscript{45} Vitamin D receptors in the nuclei
membrane regulate several defensive proteins and receptors – which are also effective against other viral infections. Receptors recognize the pathogens, like viruses, and the interaction of vitamin D with these receptors could eventually affect the expression of their related genes. In addition to these effects on the innate immune system, it also applies the regulatory impact on the adaptive immune system, which eventually results in inhibition of TH1 proliferation and shifting toward the proliferation of TH2, reduction of the oxidative compounds produced by TH1, influencing the maturation of the T-cells towards the anti-inflammatory subtypes, and prevent the further damage caused by the compounds.

Regarding the inflammatory origin of COVID-19 clinical manifestations, it is beneficial further to evaluate inflammatory factors’ role as relative prognostic factors. Previous studies have indicated that several inflammatory markers like C-reactive protein (CRP), Interleukin 6 (IL-6), and erythrocyte sedimentation rate (ESR) have the potential to determine the prognosis and the severity of patients’ clinical outcomes. Our study results showed that lower concentrations of these factors had been recorded among the patients who have consumed vitamin D supplementation. In one of the included studies, a significant decrease in Fibrinogen levels was observed after vitamin D supplementation. However, the decrease in the other evaluated inflammatory factors was not statistically significant. This could be explained according to the short follow-up duration and considering the fact that D-dimer, CRP, and ferritin have a relatively longer half-life and might need more time to reflect the impact. Therefore, it is important to determine extended follow-up durations in order to evaluate the paraclinical outcomes better.

The main advantages of the current systematic review are the rapid synthesis of the information – as the first systematic review on this topic, delivering the importance of further studies by highlighting the current clinical gaps, and providing clear instructions for further studies. The search of databases, selection of eligible studies, study assessment, and data synthesis were based on defined criteria, and performed by two independent contributors, using the proper methodological tools. However, our review had some limitations. Prominently, the number of publications on the topic is low to draw precise conclusions. It is recommended not to include both randomized controlled trials and quasi-experimental studies in one systematic review, or if included, it is recommended to analyze them separately. However, according to the low number of eligible studies, we had to include all randomized controlled trials and quasi-experimental studies together. Moreover, although the reported heterogeneity was low, the results of the meta-analysis on mortality rate might still be affected by the low number of the included studies. Also, due to the lack of studies reporting the ICU admission and clinical
outcomes, performing a quantitative analysis (meta-analysis) on these outcomes was impossible. Furthermore, the difference in the dose of the administered suppletions and the mean age of the included studies might have affected the results. We strongly recommend performing further studies, especially clinical trials, on the current topic and among different patients’ groups. Although some population-based studies have already shown the higher prevalence of severe outcomes among vitamin D-deficient patients, still, we have insufficient evidence-based knowledge about the specific effects of vitamin D supplementation of COVID-19 patients, the impact on the infected patients’ survival, mortality rate, and disease progression, the possible side-effects, the proper dosage and route of prescription, the duration of the prescription course, and the potential prophylactic effects; which may be the most beneficial and practical application of vitamin D during this medical state of emergency.

**Conclusion**

Vitamin D supplementation seems to decrease the mortality rate, the severity of the disease, and the inflammatory markers’ levels among the COVID-19 infected patients, leading to a better prognosis and increased survival rate. More studies should be conducted to determine the optimum dosage and route of vitamin D supplementation and further investigate the potential prophylactic effects.

**Acknowledgement**

The research protocol of this study was approved and supported by the Student Research Committee, Tabriz University of Medical Sciences (Grant number: 66884).

**Competing interests**

The authors declare no competing interests regarding the submission and publication of this manuscript.

**Authors’ contribution**

MAA and MSH contributed to the conceptualization and study design, LN and MSH defined the search strategy and performed the search through the databases, LN and MAA screened the results, LN and MSH critically assessed the studies, HH and MSH performed the analyses. MAA and MSH contributed to preparing the original draft of the manuscript, and LN and HH critically revised the manuscript.
References
10. Wei R, Christakos S. Mechanisms underlying the regulation of innate and adaptive immunity by vitamin D. Nutrients. 2015; 7(10): 8251-60. DOI: 10.3390/nu7105392


randomized controlled trial. Influenza Other Respir Viruses. 2019; 13(2): 176-83. DOI: 10.1111/irv.12615


46. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015; 7(6): 4240-70. DOI: 10.3390/nu7064240


48. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther. 2008; 324(1): 23-33. DOI: 10.1124/jpet.107.127209


### Tables

**Table 1. Formulated question of the study based on PICO(S)**

<table>
<thead>
<tr>
<th>Components of PICO</th>
<th>Defined as</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population/Patients</td>
<td>COVID-19 Patients</td>
</tr>
<tr>
<td>Intervention</td>
<td>Vitamin D Supplementation</td>
</tr>
<tr>
<td>Control</td>
<td>No Vitamin D Supplementation</td>
</tr>
<tr>
<td>Outcome</td>
<td>Mortality Rate, Severity of the Clinical Outcomes</td>
</tr>
<tr>
<td>Study Design</td>
<td>Clinical Trials, Quasi-Experimental, and Interventional Pilot Studies</td>
</tr>
</tbody>
</table>
Table 2. Quality assessment of the included quasi-experimental studies.

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Is it clear in the study what is the cause and what is the effect?</th>
<th>Were the participants included in any comparisons similar?</th>
<th>Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest?</th>
<th>Was there a control group?</th>
<th>Were there multiple measurements of the outcome both pre and post the intervention/exposure?</th>
<th>Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed?</th>
<th>Were the outcomes of participants included in any comparisons measured in the same way?</th>
<th>Were outcomes measured in a reliable way?</th>
<th>Was appropriate statistical analysis used?</th>
<th>Overall appraisal</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Annweiler et al. (2020)</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Include</td>
</tr>
<tr>
<td>G. Annweiler et al. (2020)</td>
<td>Y</td>
<td>U</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Include</td>
</tr>
</tbody>
</table>

Table 3. Quality assessment of the included randomized controlled trials.

| Author (year) | Was true randomization used for assignment of participants to treatment groups? | Was allocation to treatment groups concealed? | Were treatment groups similar at the baseline? | Were participants blind to treatment assignment? | Were those delivering treatment blind to treatment assignment? | Were outcomes assessors blind to treatment assignment? | Were treatment groups treated identically other than the intervention of interest? | Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analyzed? | Were participants analyzed in the groups to which they were randomized? | Were outcomes measured in the same way for treatment groups? | Were outcomes measured in a reliable way? | Was appropriate statistical analysis used? | Overall appraisal |
|---------------|---------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|---------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|------------------|
| Castillo et al. (2020) | Y | U | Y | N | U | U | Y | Y | Y | Y | Y | Y | Y | Include |
| Rastogi et al. (2020) | Y | U | Y | Y | U | U | Y | U | Y | Y | Y | Y | Y | Include |

<table>
<thead>
<tr>
<th>Author (Year)</th>
<th>Country</th>
<th>Study population (Total Number: Female/Male)</th>
<th>Age (Mean ± SD)</th>
<th>Number of patients in the Intervention group (Female: Male)</th>
<th>History of diseases – intervention group</th>
<th>History of diseases – control group</th>
<th>Type of intervention</th>
<th>Other administered drugs</th>
<th>Admission to ICU</th>
<th>Mortality</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Annweiler et al. (2020)</td>
<td>France</td>
<td>COVID-19-positive elderly nursing-home residents (66:51/15)</td>
<td>87.7 ± 9.3</td>
<td>57 (45:12)</td>
<td>NA</td>
<td>NA</td>
<td>Vitamin D3 (80,000 IU, oral, single dose)</td>
<td>Corticosteroids, Hydroxychloroquine, Antibiotics (Azithromycin/Rovamycin)</td>
<td>NA</td>
<td>NA</td>
<td>10/57</td>
</tr>
<tr>
<td>M. Castillo et al. (2020)</td>
<td>Spain</td>
<td>COVID-19 hospitalized patients (76:31/45)</td>
<td>53 ± 10</td>
<td>50 (23:27)</td>
<td>Hypertension (11/50), cardiac disease (2/50), immunosuppression/transplantation (6/50), lung disease (4/50), diabetes (3/50)</td>
<td>Hypertension (15/26), cardiac disease (1/26), immunosuppression/transplantation (1/26), lung disease (2/26), diabetes (5/26)</td>
<td>Calcifediol (0.532 mg, oral, single dose on the day of admission, continued with a half dose (0.266 mg) on day 3 and weekly)</td>
<td>Hydroxychloroquine (400 mg every 12 h on the first day, and 200 mg every 12 h for the following 5 days), Azithromycin (500 mg orally for 5 days).</td>
<td>1/50</td>
<td>13/26</td>
<td>0/50</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Description</td>
<td>Intervention Details</td>
<td>Outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>-----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Rastogi et al. (2020)</td>
<td>India</td>
<td>Asymptomatic or mildly symptomatic SARS-CoV-2 RNA-positive patients with vitamin D deficiency (25(OH)D &lt; 20 ng/ml) (40:20/20)</td>
<td>NA (Median 50.0 in the intervention group and 47.5 in the control group)</td>
<td>16 (10:6) Cholecalciferol (60,000 IU, oral, daily for 7 days) Standard care (not specified)</td>
<td>More patients tend to get rid of SARS-CoV-2 after receiving Cholecalciferol (p &lt; 0.018) with a significant reduction in fibrinogen level (p = 0.007). An overall decrease was observed in the inflammatory markers, but the changes of CRP, Procalcitonin, Ferritin, and D-dimer were not significant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G. Annweiler et al. (2020)</td>
<td>France</td>
<td>Patients hospitalized for COVID-19 in a geriatric unit (77:38/39)</td>
<td>Cancer (4/16) Hypertension (10/16) Cardiac disease (11/16)</td>
<td>16 (5:11) Cancer (13/32) Hypertension (21/32) Cardiac disease (18/32)</td>
<td>Initial bolus vitamin D3 supplementation was associated with less severe clinical outcomes and a better overall survival rate among the frail elderly. Considering the control group as the reference (HR = 1), the fully-adjusted HR for 14-day mortality was 0.37 (p = 0.28) for the intervention group.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figures

Figure 1. PRISMA Flow Diagram of the study.
**Figure 2.** Effect of vitamin D supplementation on the mortality rate of COVID-19 patients.

<table>
<thead>
<tr>
<th>Study name</th>
<th>Statistics for each study</th>
<th>Mortality / Total</th>
<th>Odds ratio and 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio</td>
<td>Lower limit</td>
<td>Upper limit</td>
</tr>
<tr>
<td>C. Auerweiler (2020)</td>
<td>0.170</td>
<td>0.039</td>
<td>0.749</td>
</tr>
<tr>
<td>M. Castille (2020)</td>
<td>0.097</td>
<td>0.004</td>
<td>2.100</td>
</tr>
<tr>
<td>G. Auerweiler (2020)</td>
<td>0.508</td>
<td>0.118</td>
<td>2.118</td>
</tr>
</tbody>
</table>